Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Dermatology | Family Medicine | Internal Medicine | Pharmacy | Journal

Back to Journal Articles

Choice of Psoriasis Treatment Affects CVD Event Rates

Last Updated: September 27, 2012.

 

Treatment with biologic agents or methotrexate linked to lower risk of CV death, MI, and stroke

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke, according to research published online Sept. 11 in the Journal of Internal Medicine.

THURSDAY, Sept. 27 (HealthDay News) -- Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke, according to research published online Sept. 11 in the Journal of Internal Medicine.

Ole Ahlehoff, M.D., of the Copenhagen University Hospital in Gentofte, Denmark, and colleagues conducted a real-world study involving 2,400 Danish patients with severe psoriasis treated with systemic anti-inflammatory drugs, including 693 patients treated with biologic agents and 799 treated with methotrexate, to measure cardiovascular disease event rates. The primary outcome was a composite end point of death, myocardial infarction, and stroke.

The researchers found that, overall, 6.0, 17.3, and 44.5 events per 1,000 patient-years occurred in patients treated with biologic agents, methotrexate, and other therapies, respectively. Using the other psoriatic therapies (including retinoids, cyclosporine, and phototherapy) as a reference cohort, the risk of cardiovascular events was lower with biologic agents (hazard ratio [HR], 0.28) and methotrexate (HR, 0.65).

"In conclusion, in this nationwide study of patients with severe psoriasis, systemic anti-inflammatory treatment with biological agents or methotrexate was associated with reduced cardiovascular disease event rates," the authors write. "Further studies are needed to confirm these findings and evaluate their clinical implications."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Insulin Sensitivity Lower in Adults Born Preterm Next: In Treated MS, Early Disease Activity Predicts Poor Outcome

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.